ORUM Total Liabilities
ORUM total liabilities. Based on the latest financial reports, ORUM (475830) has total liabilities worth ₩193.25 Billion KRW (≈ $130.96 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 475830 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ORUM (2022–2025)
Total liabilities of ORUM from 2022 to 2025. This chart illustrates how ORUM's total liabilities have evolved over time, based on quarterly financial data.
ORUM Competitors by Total Liabilities
The table below lists competitors of ORUM ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HengFeng Information Technology Co Ltd
SHE:300605
|
China | CN¥835.86 Million |
|
Wei Chuan Foods Corp
TW:1201
|
Taiwan | NT$10.66 Billion |
|
Silver Storm Mining Ltd.
V:SVRS
|
Canada | CA$35.30 Million |
|
Utah Medical Products Inc
NASDAQ:UTMD
|
USA | $4.01 Million |
|
Jaya Tiasa Holdings Bhd
KLSE:4383
|
Malaysia | RM362.93 Million |
|
Shanghai Chlor-Alkali Chemical Co Ltd B
SHG:900908
|
China | $5.72 Billion |
|
BRC Inc.
NYSE:BRCC
|
USA | $132.63 Million |
|
CARGO Therapeutics, Inc. Common Stock
NASDAQ:CRGX
|
USA | $20.91 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down ORUM's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ORUM assets under control.
Liquidity & Leverage Metrics
ORUM Total Liabilities Ratios Explained
ORUM total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ORUM's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ORUM (2022–2025)
The table below shows the annual total liabilities of ORUM from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩38.44 Billion ≈ $26.05 Million |
+19.85% |
| 2024-12-31 | ₩32.07 Billion ≈ $21.73 Million |
-85.29% |
| 2023-12-31 | ₩217.96 Billion ≈ $147.71 Million |
+46.54% |
| 2022-12-31 | ₩148.74 Billion ≈ $100.80 Million |
-- |
About ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid … Read more